

FIGURE 13.42

An example of a PEGylated bilayered phospholipid.

neoplastic meningitis; Marqibo[®] (liposomal vincristine), approved by the FDA in 2012 for the treatment of metastatic malignant uveal melanoma; EEP-ETU (liposomal paclitaxel), which is completing phase II clinical trials; and CPX-1 (liposomal formulation containing irinotecan and floxuridine), which is completing phase III clinical trials for ovarian, breast, and lung cancer.

Among the PEGylated formulations, Doxil[®] (Caelyx[®]) is a PEG–liposomal doxorubicin employed for the treatment of Kaposi’s sarcoma for more than 16 years and more recently approved for metastatic breast cancer and recurrent ovarian cancer. Doxil[®] produces mild myelosuppression, minimal hair loss, and a low risk of cardiotoxicity (Figure 13.43).⁹⁹ Thermodox[®] is another liposomal doxorubicin that releases its content upon heat. It is in phase III for treatment of hepatocellular carcinoma and recurrent chest




FIGURE 13.43

A doxorubicin-carrying PEGylated liposome (Doxil[®]).